Exact Sciences (EXAS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12
October 30, 2015 8:32 AM EDTRoth Capital maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $12.00 (from $15.00), following the company's 3Q earnings results and guidance. Management introduced 4Q volume guidance of 42k tests. EXAS also introduced 2016 volume and revenue guidance of 240k and... More
